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ABSTRACT

Background Options for patients with ventricular
tachycardia (VT) refractory to antiarrhythmic drugs and/or
catheter ablation remain limited. Stereotactic radiotherapy
has been described as a novel treatment option.
Methods Seven patients with recurrent refractory VT,
deemed high risk for either first time or redo invasive
catheter ablation, were treated across three UK
centres with non-invasive cardiac stereotactic ablative
radiotherapy (SABR). Prior catheter ablation data and non-
invasive mapping were combined with cross-sectional
imaging to generate radiotherapy plans with aim to deliver
a single 25 Gy treatment. Shared planning and treatment
guidelines and prospective peer review were used.
Results Acute suppression of VT was seen in all seven
patients. For five patients with at least 6 months follow-
up, overall reduction in VT burden was 85%. No high-
grade radiotherapy treatment-related side effects were
documented. Three deaths (two early, one late) occurred
due to heart failure.
Conclusions Cardiac SABR showed reasonable VT
suppression in a high-risk population where conventional
treatment had failed.

INTRODUCTION
Structural heart disease and impaired
ventricular function increase the risk of life-
threatening arrhythmia including ventricular
tachycardia (VT). Current approaches to the
management of VT involve the placement
of implantable cardioverter defibrillators
(ICDs), use of antiarrhythmic drugs (AADs)
and/or catheter ablation.1 Although ICDs
improve patient survival, ICD shocks can be
detrimental to quality of life and are associated with poor prognosis.2 AADs have modest
efficacy and can have significant side effects.3
Catheter ablation is effective for control of VT
and reduction in ICD shocks, but also represents a prolonged, technically challenging

Key questions
What is already known about this subject?
►► Patients with uncontrolled ventricular arrhythmias

related to cardiac scar tend to have a poor prognosis and significant morbidity. This is related to both
frequent arrythmia episodes and treatment thereof,
as well as their underlying cardiac dysfunction.
►► Stereotactic radiotherapy (SABR) is an established
treatment for many cancers.

What does this study add?
►► We report initial UK experience with cardiac SABR

treatment of refractory ventricular arrhythmias.
►► Across three centres, a multidisciplinary approach

with collaboration between cardiology (electrophysiology and imaging) and oncology teams (clinical
oncology and medical physics) was employed to
successfully deliver treatment.

How might this impact on clinical practice?
►► This represents an exciting and novel non-invasive

treatment option, but further clinical trials, refinements in technique and mechanistic studies are
needed.

procedure that may pose higher risks to more
frail patients.4 5
Stereotactic radiotherapy (SABR) is a technique for treating targets anywhere in the
body, made possible by advances in radiation
treatment planning, imaging guidance and
delivery systems. High doses of radiation can
be precisely delivered to defined targets, with
a steep drop off in dose gradients to minimise
dose to surrounding normal tissues. SABR
achieves very high local tumour control rates
with low toxicity and has been widely adopted
in the management of a range of cancers,
including lung, prostate, liver, kidney
and pancreas.6 Following the first patient
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treatment in 2012,7 several single centre case series8 9
and a Phase I/II study (EP-guided Noninvasive Cardiac
Radioablation for treatment of Ventricular Tachycardia
(ENCORE-VT))10 have demonstrated the potential for
non-invasive cardiac SABR treatment to control VT where
conventional treatment has failed. However, to date the
entire literature describes less than 60 patients treated by
this novel approach.11–13 Recognising the urgent need for
more effective treatments in patients with refractory VT,
three UK tertiary cardiac centres agreed to collaborate in
developing cardiac SABR services aiming to maximise the
benefits of combined experience of a novel technique.
We now report our initial experiences.

METHODS
Each institution obtained formed a local cardiology
and oncology working group and obtained institutional
approval for use of the established SABR service in a
novel compassionate use indication. Working with the
ENCORE-
VT trial group,10 planning, treatment and
follow-up guidelines were developed and shared.
Over the period June 2019 to January 2020, seven
patients with recurrent VT despite AAD use and prior
invasive VT ablation or contra-indication to invasive VT
ablation underwent cardiac SABR treatment. All patients
received acute initial stabilisation measures including
correction of electrolytes, optimisation of heart failure
management and additional AADs where appropriate.
All patients were discussed in cardiology and oncology
meetings at each local centre, and also with the other
two UK centres prior to proposing SABR treatment. All
patients gave interdisciplinary informed consent and
treatment was delivered on outpatient basis with option of
overnight hospital admission post-treatment permitted at
clinician discretion due to novelty of cardiac SABR treatment. Patient characteristics are summarised in table 1.

Pre-treatment workup
Four-
dimensional (4D) high-
resolution cardiac and
respiratory cycle (radiotherapy planning) CT scans were
both performed with intravenous contrast (and oral
contrast if deemed necessary to demonstrate gastrointestinal tract for inferior wall targets) and co-registered. The
cardiac CT scan was used to define cardiac structures in
particular regions of scar based on myocardial wall thickness, and the radiotherapy planning CT scan was used to
define extracardiac structures. Cardiac MRI and nuclear
medicine scans were also used to define myocardial scar
where available.
Clinical 12 lead ECGs of VT and prior invasive electrophysiology data, including electroanatomic voltage and
activation maps, were reviewed by two electrophysiologists from each centre to agree on VT exit sites. In six of
seven patients, inducibility of clinical VT and other VTs
as tolerated was confirmed by a non-invasive electrophysiology study (programmed stimulation through ICD)
combined with body surface mapping using the View into
Ventricular Onset (VIVO system - Catheter Precision).
In general, the integration of structural and ECG data
was performed manually by side to side comparison and
clinician consensus. Use of the 17 segment cardiac model
was encouraged to facilitate communication between
physicians and centres. In Sheffield, an additional step
was developed to fuse imaging data (DICOM format) and
electroanatomic map (EAM)/VIVO data (.dif or .vtk)
using Mimics Innovation Suite, V.23 (Materialise, Leuven,
Belgium). Deformable registration techniques were used
to fuse the various modalities using the CT as the primary
fixed image for planning review. This permitted a three-
dimensional target to be defined directly on the myocardial surface and a target volume generated by extruding
the surface through the myocardium. This volume was
exported to directly generate a DICOM RT structure in
Eclipse (n=2, Varian Medical Systems). For the two other

Table 1 Demographics
Patient

Age

Gender

LVEF

Aetiology

NYHA

Device

Antiarrhythmic drugs

Prior catheter ablation

1 (STH)

70s

M

20

Myocarditis

III

CRTD

2

2 (NUTH)

70s

F

30

Idiopathic

IV

CRTD

A 300 mg once a day
R 500 mg two times per day
(intolerant Me)
A 200 mg once a day

3 (JCUH)

70s

M

45

Ischaemic

II

ICD

A 200 mg once a day

1

4 (NUTH)

60s

M

35

Ischaemic

II

ICD

A 200 mg once a day

3

5 (STH)

60s

M

15

Ischaemic

II

CRTD

Me 300 mg three times a day
(prior use of A, R)

2

6 (NUTH)

70s

F

25

Ischaemic

III

ICD

2

7 (JCUH)

70s

F

20

Ischaemic

III

CRTD

A 200 mg once a day
(prior use of Me, P)
A 200 mg once a day

3

0

A, amiodarone; CRTD, biventricular implantable defibrillator; F, female; ICD, implantable defibrillator; JCUH, James Cook University Hospital
Middlesbrough; LVEF, left ventricular ejection fraction; M, male; Me, mexiletine; NUTH, Newcastle Hospitals NHS Foundation Trust; NYHA,
New York Heart Association class; P, propafenone; R, ranolazine; STH, Sheffield Teaching Hospitals; VIVO, view into ventricular onset (non-
invasive mapping).
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Figure 1 Illustrative workflow—cardiac CT imaging is
combined with electrophysiology mapping data into a single
three-dimensional model used to define a target region for
import into radiotherapy planning software.

centres, segments of scar adjacent to VT exit site location(s) were manually delineated for gross target volume
(GTV) on the respiratory gated 4D radiotherapy planning scan using either Monaco (n=2, Middlesbrough,
Elekta) or Raystation (n=3, Newcastle, RaySearch Laboratories) software. Illustrative workflow for the image
fusion approach to define the cardiac target is presented
in figure 1 and a summary of target selection data is given
in table 2.
Cardiac GTV margins were expanded to account for
cardiac and respiratory motion to generate the internal
target volume. Finally, a 3–5 mm margin was added to
account for variation in patient positioning thus generating the final planning target volume (PTV). Treatment
plans were produced with aim to achieve single dose
25 Gy treatment to 95% of PTV—see example in figure 2.
Dose constraints to off target structures such as thoracic
and abdominal organs were based on the ENCORE-VT
protocol and American Association of Physicists in Medicine guidelines.14 15 Dose was also minimised to device

Figure 2 Example cardiac SABR plan from patient 3—top
panel ‘isodose’ areas show how 25 Gy SABR treatment is
focused on cardiac target area, bottom panel—dose-volume
histogram demonstrating how treatment to off-target organs
at risk is minimised. CORS, coronary arteries; PTVoptim,
optimised and prescribed planning target volume; SABR,
stereotactic radiotherapy.

lead tips and proximal coronary arteries. In two patients
with inferior wall targets, the stomach was in close proximity and at risk of exceeding pre-specified 17.4 Gy organ
at risk limit. Two different approaches were used—in
patient 1, the overall SABR dose was reduced to 20 Gy,
while in patient 3, stomach plus 8 mm margin was removed
from the PTV. Further detailed information on SABR
plans is provided in the online supplemental data table
1 as per International Commission on Radiation Units
and Measurements (ICRU) 91 reporting standards.16

Table 2 Targeting details
Patient

Scar segments (MRI/CT)

Clinical VT
(12 lead ECG)

VIVO NIPS—VT exit

Segments targeted

Treatment

1 (STH)
2 (NUTH)

10, 11, 15,16
5 (EAM)

10, 15
N/A*

Not performed
1, 5, 6, 17

10, 15
1, 5, 6, 17

Jun 2019
Jun 2019

3 (JCUH)

3, 4, 9, 10

10

3, 4, 10

Jul 2019

4 (NUTH)

4, 10, 15

4

4, 10

Dec 2019

9, 10, 15

Jan 2020

5 (STH)
6 (NUTH)
7 (JCUH)

3, 4, 9, 10, 15
13, 14, 16, 17
2, 3, 4, 5, 8, 9, 10, 11, 14

15
13, 17
N/A*

3, 4
10
9, 10
14, 16
14

13, 14, 16, 17
2, 3, 8, 9, 14

Jan 2020
Jan 2020

*Device electrogram data available only.
EAM, electroanatomic map; JCUH, James Cook University Hospital Middlesbrough; NIPS, non invasive programmed stimulation; NUTH,
Newcastle Hospitals NHS Foundation Trust; STH, Sheffield Teaching Hospitals; VIVO, view into ventricular onset (non-invasive mapping); VT,
ventricular tachycardia.
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Table 3 SABR treatment details
Patient

VTs targeted Planning target volume (mL) Beam on time (min) Linear accelerator Total time in room (min)

1 (STH)
2 (NUTH)

1
3

65.8
57.5

7
5

Varian
Varian

60
28

3 (JCUH)

2

139.0

12

Elekta

40

4 (NUTH)

1

121.1

5

Varian

35

5 (STH)

2

89.5

12

Varian

45

6 (NUTH)
7 (JCUH)

2
1

101.5
87.4

5
8

Varian
Elekta

33
30

JCUH, James Cook University Hospital Middlesbrough; NUTH, Newcastle Hospitals NHS Foundation Trust; SABR, stereotactic radiotherapy;
STH, Sheffield Teaching Hospitals; VT, ventricular tachycardia.

A remote peer-review process was set up between three
UK centres and with Center for Non-invasive Cardiac
Radioablation, Washington University, St Louis. Anonymised clinical data and treatment plans were uploaded to
a secure server and online meetings were held to review
case data.
Treatment delivery and follow-up
During treatment with the Linear Accelerator (Varian
Medical Systems/Elekta), departmental patient immobilisation techniques were used which included use of
abdominal compression in cases where it was observed
to help limit respiratory movement. A Day 0 ‘practice
run’ was recommended to give experience with individual patient positioning and cone beam CT registration. Matching was performed on bony structures, device
leads and left ventricle outline. Treatment used intensity-
modulated planning and delivery. Single fraction high-
dose treatment was delivered during free breathing
without any cardiac fiducial marker gating. See table 3 for
summary of treatment delivery. Overnight hospital admission was left at clinician discretion. Most patients had an
indication for oral anticoagulation (usually atrial fibrillation), but if not anticoagulation for 4 weeks post SABR
was recommended. Patients were then followed with a
combination of telephone and in person appointments
at 6 weeks and then every 3 months, and through the
remote monitoring function of their ICDs. Transthoracic
echo was undertaken at 6 weeks, no routine follow-up CT
imaging was undertaken. Following the first 6 weeks after
SABR, clinicans were encouraged to reduce antiarrhythmics if possible. Patient ICD settings including monitor
zones were programmed at the discretion of the local
centre, with the common aim of maximising VT detection. During follow-up, all device detected VT episodes
were reviewed by an electrophysiologist to confirm the
diagnosis.
RESULTS
Acute observations—first 60 days
All patients were successfully treated—see table 3 for
specific details of target volume and treatment time. In
patient 2, acute termination and suppression of sustained
4

VT was observed during SABR treatment. Troponin
measurement taken 24 hours post SABR in two patients
remained in normal range in patient 1 and showed an
insignificant rise to less than two times upper limit normal
in patient 5. Observed radiotherapy toxicity was limited
to Common Terminology Criteria for Adverse Events
(CTCAE) Grade 1 fatigue in two patients and no toxicity
in terms of lung, cardiac, GI side-effects was observed
clinically. No change in LV function was seen on echo
at 6 weeks. Patient 1 had an acute flare up of VT post
SABR that required temporary escalation of amiodarone
and ranolazine doses for 2 months. Patient 3 also experienced further VT post SABR with a different inferior exit
site that required escalation of AADs and then underwent
repeat catheter ablation 7 weeks after SABR. No significant changes were noted in the bipolar endocardial
voltage map to reflect recent SABR treatment.
Despite acute reduction of VT episodes, patient 2 and
patient 7 both died of progressive heart failure within
4 weeks of treatment. Patient 2 was challenging to treat
due to lack of anatomic scar on CT/MRI and multiple VT
exit sites documented clinically and at VIVO non invasive programmed stimulation (NIPS) involving anterior,
posterolateral, summit and apex regions of LV. Both of
these patients were either New York Heart Association
(NYHA) class IV status at the time of treatment or deteriorated to class IV shortly afterwards. Postmortem histology
was obtained in patient 7 with kind permission from
patient’s family. No acute radiotherapy changes were
detected in surrounding organs, though acute changes
in the heart were observed—see figure 3. Myocardium in
the vicinity of the treated area showed established fibrosis
from prior ischaemic damage. Non-fibrotic myocardium
showed an increase in capillary vascularity as might be
expected in relation to radiation treatment. No other
histologic features of radiation exposure such as acute
necrosis, changes in blood vessel wall, thrombosis, fibroblast proliferation or nuclear atypia were seen.
VT burden and survival
Of the remaining five patients, patient 1 died 9 months
after treatment due to progressive heart failure, while
the others remain alive. Comparing the 6 months prior
Lee J, et al. Open Heart 2021;8:e001770. doi:10.1136/openhrt-2021-001770
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Figure 3 Panel A shows myocardium with some increase in capillary vascularity related to treatment, but minimal fibrosis,
within tissue sampled from the targeted area. Panel B shows myocardial fibrosis close to but outside of the targeted area,
related to pre-existing myocardial ischaemia.

to treatment with 6 months after treatment we observed
85% reduction in VT episodes—see figure 4, though
in patient 4, the VT detection zones were suboptimally
programmed prior to SABR treatment, and the number
of episodes of VT prior to SABR was almost certainly
undercounted. The majority of VT episodes were either
non-sustained or terminated with antitachycardia pacing
(ATP). Over the same time period, total ICD shocks
across the whole group were reduced from seven pre-
treatment to none post-treatment.
Following SABR, amiodarone dose was successfully
reduced to 100 mg (n=2) or stopped (n=3), with the aim
of reducing long-term toxicity and improving quality of
life.
DISCUSSION
Our study shows effective (85%) VT suppression by
cardiac SABR, applied on compassionate use basis, in a
group of patients with heart failure and recurrent VT and
few therapeutic options. Over the past decades, advances
in medical therapy and cardiac resynchronisation have
yielded improvements in heart failure survival with
reduced sudden death.17 18 Successful VT management is
also associated with improved survival,19 and reduction in
VT episodes improves quality of life by less frequent ICD

therapy, fewer hospital admissions and a reduction in
AAD use.20 However, we accept that we did not formally
measure quality of life in this series, and follow-up is
limited to 6 months. We have chosen to report total
VT episodes as the primary outcome to present the full
‘biologic’ treatment effect; although ICD shock therapy
may be considered a more clinically relevant endpoint,
the total numbers of ICD shocks were small in this series.
Given the limited efficacy of second line AADs beyond
amiodarone and significant challenges of catheter ablation in frail patients,4 21 non-invasive SABR delivered on
an outpatient basis could play an important role in VT
management and symptom improvement. The extent
of VT suppression seen in our cohort is in keeping with
other series. Robinson et al reported ~90% suppression
of VT in 19 patients,10 Neuwirth et al 87% in 10 patients
out to median 28 months follow-up.9 Gianni et al on the
other hand reported good initial effects of treatment in
five patients followed for a median 12 months, but significant late recurrences of VT requiring re-escalation of
AADs and repeat ablation in three patients.22 Lloyd et al
reported 10 patients with more modest overall efficacy in
terms of VT burden (69% reduction), ATP (48% reduction) and ICD shocks (68% reduction) in an advanced
heart failure population.23

Figure 4 VT episodes in five patients that had at least 6 months follow-up comparing 6 months prior to SABR treatment (red)
with 6 months post (blue). SABR, stereotactic radiotherapy; VT, ventricular tachycardia.
Lee J, et al. Open Heart 2021;8:e001770. doi:10.1136/openhrt-2021-001770
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We emphasise that in this series SABR treatment was a
‘last resort’ procedure for high-risk patients. Unsurprisingly, we observed two acute and one mid-term deaths
from non-arrhythmic causes in a cohort with advanced
heart failure24—all three patients that died were NYHA
class III or IV at SABR treatment. The Washington University group has recently reported that long-term survival
of their 19 SABR-treated patients may be predicted by
baseline cardiac function.25 Survivors (n=8, survival
for median of 27.7 months) versus those who received
cardiac transplant or died (n=11) had smaller cardiac
volumes on echo and less myocardial scar on MRI. As
SABR treatment places less demand on the patient, it is
an attractive option for frail patients or those with more
advanced heart failure, yet such patients may to be too
sick to gain prognostic benefit. Nevertheless, given the
ability of SABR to treat substrates inaccessible to catheter ablation, it remains an attractive option for further
investigation.
Cardiac SABR target selection is a challenge requiring
integration and registration of imaging and functional
data. In this series, and reflecting current worldwide
experience and literature, we used a range of approaches
from manual delineation methods to more sophisticated
computer-assisted visualisation methods still under development.26–28 The optimum dose and delivery platform
for cardiac SABR is yet to be established. We used a single
fraction 25 Gy regime as reported by all groups previously.
While this did largely suppress VT (in one case at point
of delivery), we also saw some short-term VT recurrences
which may reflect incomplete substrate ablation. Like
Robinson et al we employed gantry-based linear accelerator systems, while Neuwirth et al and Gianni et al used
the Cyberknife platform delivering radiotherapy via a
robotic arm.10 22 Cyberknife treatment times are reported
as longer—median 80 min versus 15 min, which could
make consistent patient positioning and accurate delivery
more challenging, although lower treatment volumes
have been reported which might reduce off target effects.
At present, the mechanism(s) of action of cardiac
SABR are not established. Alongside other reports, we
observed acute VT suppression that seems too rapid to
be explained by the development of radiation fibrosis.
Our early postmortem data within weeks of SABR demonstrated acute vascular changes but have not shown significant tissue injury or acute fibroblast proliferation, and
this is consistent with the postmortem findings of little
or no necrosis described by Cuculich et al and also Krug
et al at similar time frames—3 weeks and 57 days post
SABR, respectively.8 29 More recently, a four patient series
ranging from 12 to 250 days post SABR treatment has
reported both cardiac histology and electron microscopy
findings of cellular necrosis and fibrosis.30 Our observation that troponin levels do not appear to rise acutely,
although measured in only two patients, also makes early
necrosis as observed in radiofrequency ablation unlikely.
Preclinical studies do offer more scope to study radiobiologic effects. Studies in porcine and canine atrial models
6

have confirmed scar formation at 4–6 months with high
dose (>32 Gy) treatment.31 32 Rabbit and dog models have
reported a paradoxical acute increase in cardiac conduction velocity following heavy ion irradiation, mediated
through increased Connexin 43 expression.33 Data taken
at serial timepoints up to 4 weeks post irradiation in
a rat model did not show necrosis or apoptosis, rather
interstitial and intracellular oedema, reflected in slowed
conduction with prolongation of PR and QT intervals.34
However, any perturbation of myocardial conduction
whether increase or decrease may be sufficient to prevent
re-entrant VT and most recent data again points to a
‘supraphysiologic’ phenotype induced by radiation.35
The acute and late side effects of radiotherapy also
need consideration, including those affecting the heart
itself. We did not perform follow-up imaging apart from
echo and did not document any clinically significant
acute side effects, but long-term effects including pericardial fibrosis and constriction, or coronary and valve
disease are well-documented in cancer survivors and are
a concern.36 There is increasing recognition that even at
12–24 months, survival may be adversely affected in non-
small cell lung cancer patients receiving higher dose off
target treatment to the heart.37 Infrequent late effects of
cardiac SABR treatment including pericarditis and gastric
fistula have been reported as the follow-up of patients
treated by this novel technique increases.38 Therefore, it
is important to report all experience of this treatment, to
help refine cardiac SABR techniques.
The unique features of this report are the collaborative
approach to application of cardiac SABR across several
centres within a larger health network (National Health
Service), and the use of different planning and treatment
delivery platforms. This report also presents the first use
of a remote peer review system for cardiac SABR. SABR
is a well-
established oncology clinical service and the
infrastructure is present in almost all NHS radiotherapy
centres in the UK. There is also an established national
multidisciplinary group (UK SABR Consortium) that
provides expert consensus, quality assurance and liaison
with clinical commissioners. The approach to cardiac
SABR used so far is a direct translation from standard
radiation oncology practice but further refinements will
be possible, including improved or semiautomated three-
dimensional target delineation, ECG or respiratory-gated
treatment delivery, and optimisation of dosing and fractionation regimes.
CONCLUSIONS
Our report confirms, in a UK multicentre setting, prior
observations about the short-
term and medium-
term
efficacy and safety of cardiac SABR for control of VT in
a high-risk population that was refractory to standard
approaches. There is still much to learn about this promising, novel non-invasive treatment and further research
is already underway including clinical trials and mechanistic studies.
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Supplementary data table

Volume (ml)

Doses (Gy)

Patient
1 (STH)

ITV
15.1

PTV*
82.0

PTV_optim
65.8

2 (NUTH)

15.9

57.5

57.5

3 (JCUH)

63.2

140.8

139.0

4 (NUTH)

47.4

123.2

121.1

5 (STH)

34.0

101.0

89.5

6 (NUTH)

47.1

101.5

101.5

7 (JCUH)

41.9

88.7

87.4

Dose
point
D2%
D50%
D98%
D2%
D50%
D98%
D2%
D50%
D98%
D2%
D50%
D98%
D2%
D50%
D98%
D2%
D50%
D98%
D2%
D50%
D98%

ITV
24.1
22.4
19.4
32.2
30.0
28.1
32.0
28.6
23.4
32.8
28.4
26.1
29.7
28.1
23.8
33.3
30.1
28.0
32.2
28.8
26.1

PTV
23.9
21.1
17.9
32.0
28.6
23.4
31.6
27.9
16.8
32.5
27.6
22.6
29.5
27.3
17.5
32.9
28.9
24.0
31.8
27.9
23.8

PTV_optim
23.9
21.6
19.8
31.6
27.9
24.3
32.5
27.7
24.3
29.6
27.4
24.3
31.8
27.9
24.4

STH = Sheffield Teaching Hospitals, NUTH = Freeman Hospital Newcastle upon Tyne,
JCUH = James Cook University Hospital Middlesbrough. ITV = internal target volume, PTV
= planning target volume, PTV_optim = optimised and prescribed planning target volume.
*JCUH used ITV+3mm to generate PTV, other centres used ITV +5mm

Lee J, et al. Open Heart 2021; 8:e001770. doi: 10.1136/openhrt-2021-001770

